FindTrial
Sign In

An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522664-32-00
Acronym
ANX005-GBS-05
Enrollment
10
Registered
2025-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Guillain Barre Syndrome

Brief summary

Noncompartmental PK parameters of ANX005 in serum through Week 2

Detailed description

Change from Baseline in free C1q protein concentration in serum through Week 2 • Change from Baseline in percent complement pathway activity in serum through Week 2, Medical Research Council (MRC) sumscore change from Baseline at Week 1

Interventions

DRUGANX005

Sponsors

Annexon Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Noncompartmental PK parameters of ANX005 in serum through Week 2—

Secondary

MeasureTime frame
Change from Baseline in free C1q protein concentration in serum through Week 2 • Change from Baseline in percent complement pathway activity in serum through Week 2, Medical Research Council (MRC) sumscore change from Baseline at Week 1—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026